Search results
Added:
1 year ago
Recorded during HFA 2024, Dr Caroline Coats, Glasgow University, UK, and Dr Ahmad Masri, Oregon Health and Science University, US, collaborate to explore the pivotal advancements in managing hypertrophic cardiomyopathy unveiled at the conference.This programme is thoughtfully divided into four chapters, facilitating a smooth journey through the latest HCM trial data, including a comprehensive…
View more
Added:
1 year ago
ACC 2025 - Principal results from autologous cell therapy in patients with heart failure with reduced ejection fraction (HFrEF) show favourable safety outcomes, however, the study did not meet its primary efficacy outcome using 6 minute walking rests as 3rd F-S tier.Dr Amish Raval (UW Health University Hospital Interventional Cardiology Clinic, WI, US) joins us onsite at ACC to discuss the…
View more
Added:
1 year ago
Added:
1 year ago
ACC 2025 - First-in-human results from MyPEAK-1 show Tn-201 treatment in adults with Mybpc3-associated hypertropic cardiomyopathy was feasible and safe.Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at ACC 2025 to discuss phase Ib/2a results from the first-in-human, non-randomized study investigating the safety and early efficacy of Tn-201, an adeno-associated virus serotype 9 gene…
View more
Added:
5 months ago
AHA Scientific Sessions 2025 – Dr Ambarish Pandey (University of Texas Southwestern Medical Center, US) presents results from the POLY-HF trial (NCT04633005), evaluating a polypill strategy combining multiple evidence-based medications for heart failure with reduced ejection fraction.This single-center randomized trial enrolled 212 patients with HFrEF (ejection fraction ≤40%) who were not…
View more
Start date:
Nov 17, 2025
Breakthrough Mineralocorticoid Receptor Antagonists in Cardiovascular Care brings together renowned cardiovascular experts Dr Vijay Chopra, Dr Javed Butler, Dr Dinesh Khullar, and Prof John McMurray to address critical challenges in heart failure management and hypertension treatment. This comprehensive session explores innovative approaches to mineralocorticoid receptor antagonist (MRA) therapy,…
View more
Added:
1 year ago
AHA Conference 2024 - 128-week results of VALOR-HCM investigating mavacamten treatment for patients with hypertrophic cardiomyopathy (HCM) referred for septal reduction therapy (SRT) procedures.Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at AHA Conference to discuss the findings from VALOR-HCM (NCT04349072).VALOR-HCM is a randomized, double-blind, placebo-controlled, phase 3…
View more
Risk Prediction of CVD in the Asia-Pacific Region
Added:
1 year ago
Original Research
Added:
7 months ago
Source:
Radcliffe Cardiology
The ODYSSEY-HCM trial, evaluating the cardiac myosin inhibitor mavacamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (HCM), did not meet its dual primary endpoints for improving functional capacity or patient-reported symptoms.¹ The findings were presented at the European Society of Cardiology (ESC) Congress 2025 and simultaneously published in the New England…
View more
Added:
2 years ago
ACC 2024 — Late-breaker host Dr Harriette Van Spall (McMaster University, CA) sits down with Dr James L. Januzzi (Massachusetts General Hospital & Harvard Medical School, US) to discuss the latest findings from the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure trial (ARISE-HF, Applied Therapeutics, Inc) (NCT04083339).This phase 3 multicenter, randomized,…
View more